During its presentation at the 44th Annual J.P. Morgan Healthcare Conference, Revvity’s CEO outlined the company’s shift from an industrial-focused business to a specialized life sciences and diagnostics leader. Over the past 12 months, Revvity has rebalanced its revenues so that analytical instruments now represent nearly half of total sales, up from one-third, while diagnostics and small-molecule preclinical services each contribute roughly a quarter. Management reiterated its commitment to multi-omics, biomarker identification and advanced imaging, citing a projected compound annual growth rate of 8%–10% in those segments over the next three years based on current sales funnels and strategic partnerships.

Revvity announced preliminary estimates showing reported revenue growth of approximately 6% and organic growth of 4% for Q4 2025, driven by strong demand in contract research and diagnostics services. This translates to roughly $772 million in quarterly sales. For the full year, reported revenue is expected to reach about $2.855 billion, a 4% increase year-over-year, with organic growth of 3%. The company now anticipates adjusted earnings per share to exceed the previously guided $5.00 upper bound, reflecting improved operating leverage and disciplined expense management.

Revvity has entered into a collaboration with Eli Lilly to integrate its TuneLab AI models into the Signals Xynthetica platform, aiming to accelerate federated drug discovery workflows. Under the agreement, Revvity will provide its secure cloud infrastructure and informatics tools to host Lilly’s proprietary algorithms, enabling joint customers to access predictive screening and molecular optimization capabilities at scale. This alliance is expected to contribute incremental revenue beginning in mid-2026 and enhance Revvity’s position in the fast-growing computational biology market.